Matches in Wikidata for { <http://www.wikidata.org/entity/Q66077300> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q66077300 description "clinical trial" @default.
- Q66077300 description "ensayu clínicu" @default.
- Q66077300 description "klinisch onderzoek" @default.
- Q66077300 description "клінічне випробування" @default.
- Q66077300 description "կլինիկական փորձարկում" @default.
- Q66077300 name "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 name "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 type Item @default.
- Q66077300 label "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 label "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 prefLabel "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 prefLabel "2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy" @default.
- Q66077300 P1050 Q66077300-B7DBA7CE-D30A-4151-BA8C-1B62A1248CF0 @default.
- Q66077300 P1132 Q66077300-2B37D4D5-62A3-4E12-9447-831824ACF4EB @default.
- Q66077300 P1476 Q66077300-FF565EE9-790F-4D0A-979F-75535B964EA0 @default.
- Q66077300 P2899 Q66077300-E9B2941C-4ED8-444E-B8ED-0158B96824E8 @default.
- Q66077300 P3098 Q66077300-9496D3DB-4BD4-4D68-995E-AE02D389104D @default.
- Q66077300 P31 Q66077300-1FACA46F-1801-4473-8F34-E61C182CC5EF @default.
- Q66077300 P4135 Q66077300-782E1863-8029-44E5-97F6-57F548A1689F @default.
- Q66077300 P4844 Q66077300-3F10DAB9-30E6-42D1-91DD-4BD10CF7C97E @default.
- Q66077300 P4844 Q66077300-A2BF1F56-FCC5-456D-AB49-84EB4EADFB69 @default.
- Q66077300 P4844 Q66077300-AFD0C408-D853-4059-B7A6-E7237F91237C @default.
- Q66077300 P580 Q66077300-56650B0E-DC71-4464-AAD4-66A10F0BCA9D @default.
- Q66077300 P582 Q66077300-063A63EB-EF67-455A-B596-6F8118A00EF3 @default.
- Q66077300 P6099 Q66077300-4298F684-76C6-425E-8E02-1DE432CDB086 @default.
- Q66077300 P8363 Q66077300-E14F1119-2891-4A16-B9D8-400D4F7BBA91 @default.
- Q66077300 P1050 Q467635 @default.
- Q66077300 P1132 "+0" @default.
- Q66077300 P1476 "2015-09: A Phase II Randomized, Open-label Study of Anti-SLAMF7 mAb During Maintenance Therapy Versus Standard Maintenance Therapy in Gene Expression Profiling (GEP)- Defined Low Risk Multiple Myeloma Patients With High Risk Cytogenetic Abnormalities" @default.
- Q66077300 P2899 "+18" @default.
- Q66077300 P3098 "NCT03000634" @default.
- Q66077300 P31 Q30612 @default.
- Q66077300 P4135 "+75" @default.
- Q66077300 P4844 Q3723645 @default.
- Q66077300 P4844 Q408524 @default.
- Q66077300 P4844 Q425681 @default.
- Q66077300 P580 "2017-05-01T00:00:00Z" @default.
- Q66077300 P582 "2023-05-01T00:00:00Z" @default.
- Q66077300 P6099 Q42824440 @default.
- Q66077300 P8363 Q78089383 @default.